SCHEMBL2184852

SCHEMBL2184852

c1ccc(COc2ccnc3ccc(-c4cccc(-c5nccs5)n4)cc23)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.48
INSR P06213 1/20 0.39
ALK Q9UM73 1/20 0.39
RAB9A P51151 1/20 0.38
PDPK1 O15530 1/20 0.38
CARM1 Q86X55 4/20 0.38
PRMT1 Q99873 4/20 0.38
CDC7 O00311 1/20 0.38
PIK3CA P42336 1/20 0.37
FFAR1 O14842 1/20 0.37
CTSA P10619 2/20 0.36
MCL1 Q07820 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12391437 0.83 HPGD (0.37) SYKRAB9AMEN1ALDH1A1HPGD
SCHEMBL2183445 0.81 PLAU (0.40) PIK3CAKDM4EMEN1ALDH1A1LMNA
SCHEMBL2184913 0.81 MET (0.39) PIK3CAKDM4EMEN1ALDH1A1LMNA
SCHEMBL12367287 0.79 SYK (0.39) SYKRAB9AMCL1
SCHEMBL2185604 0.79 MCL1 (0.35) SYKRAB9AMCL1
SCHEMBL2185432 0.79 RAB9A (0.43) SYKRAB9APDPK1MCL1ALDH1A1
SCHEMBL27843181 0.75 RAB9A (0.40) SYKRAB9APDPK1PIK3CAMCL1
SCHEMBL17704347 0.74 RAB9A (0.48) SYKRAB9APDPK1CDC7MCL1
SCHEMBL16159716 0.74 PDPK1 (0.49) SYKRAB9APDPK1CDC7MCL1
SCHEMBL16159692 0.71 RAB9A (0.53) SYKRAB9APDPK1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735424-B2 Bicyclic kinase inhibitors NOVARTIS AG (CH) 2014-05-27 US disclosed
US-8735424-B2 Bicyclic kinase inhibitors NOVARTIS AG (CH) 2014-05-27 US disclosed
US-20110195980-A1 Bicyclic Kinase Inhibitors NOVARTIS AG (CH) 2011-08-11 US disclosed
US-20110195980-A1 Bicyclic Kinase Inhibitors NOVARTIS AG (CH) 2011-08-11 US disclosed
EP-2342190-A1 BICYCLIC KINASE INHIBITORS Novartis AG (CH) 2011-07-13 EP disclosed
WO-2010026121-A1 BICYCLIC KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195980-A1 Bicyclic Kinase Inhibitors PIM1, PIM2, PIM3 SYK 552/4885INSR 2141/4885ALK 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.